Insights
Insights

Improving your search strategy: randomised controlled trial filters (1/2)
A search filter is a pre-written search strategy (string of search terms) that is designed to retrieve studies with a particular methodology or focus from a specific database and platform (1). The most common filters are designed to retrieve randomised controlled trials (RCTs), which are widely considered the most robust form of research for evidence-based medicine (2, 3).

Applying health technology assessment requirements to your global value dossier
The global value dossier (GVD) is an essential tool used to internally align the global strategy and externally communicate the value of a product. The GVD presents evidence-based messaging to convey the product value story and is a primary resource for affiliates. Unlike a Health Technology Assessment (HTA) submission, the GVD is strategic, bespoke, and not confined by restrictive templates and requirements.

Collaborative webinar: economic modelling in rare diseases
It can be challenging to develop an economic model in rare diseases that optimises HTA and reimbursement outcomes. It can be difficult to fully capture the effects of the disease and the benefits of treatment whilst using sufficiently robust data to minimise uncertainty. This webinar will introduce a new approach in which multiple companies collaborate to develop a core economic model and common data set. An approach that aims to optimise HTA and reimbursement outcomes for all new treatments in a rare disease.

COVID-19, evidence-based medicine and standards for HTA
When Archibald Cochrane formulated his vision for evidence-based medicine (EBM), it was driven by an absence of reliable, robust evidence supporting frequently accepted medical interventions. His observations provoked meticulous evaluations of novel interventions, which subsequently emphasised the need for high-quality evidence in medicine (1). Today, EBM has defined modern medicine; its goal is to minimise the uncertainties in clinical decision-making (2) and to increase the use of high-quality evidence. In practice, this involves the integration of clinical expertise and patient values with the best available evidence (3).

Evidence search for medical devices: challenges and recommendations
In principle, the process of searching for published evidence for medical devices is no different from other health technologies. The NICE process guidelines do not specify alternative sources or a different level of rigour for any kind of health technology. However, when conducting searches for medical devices, the evidence base should be approached differently in order to optimise the precision and sensitivity of the search.

Exploring the NICE MTEP process for developing medical device guidance
The NICE Medical Technologies Evaluation Programme (MTEP) evaluates novel medical devices and diagnostics for use within the National Health Service (NHS). There are currently 3 outputs from the programme: medical technologies guidance (MTGs), diagnostics guidance (DGs) and medical innovation briefings (MIBs). A fourth type of guidance, digital health technologies (DHTs), is being piloted.

The NICE HST process (3/3) – challenges associated with appraising treatments for ultra-rare indications
In previous blog posts, we explored the origins of NICE’s Highly Specialised Technologies (HST) process and compared it with the Single Technology Assessment (STA) process. In this blog, we review the first 10 HST appraisals and identify key issues raised by the Evidence Review Groups (ERGs)

Reporting current research with living systematic literature reviews
Although considered the gold standard of quality research, systematic literature reviews (SLRs) are very resource intensive (e.g. long timeline, high budget) [1]. This, in combination with the broader issue that “research outpaces understanding,” SLRs get quickly out-of-date [2].

The NICE HST process (2/3) – differences in assessment of cost-effectiveness between the HST and STA
In a previous post, we discussed the origins of the NICE Highly Specialised Technologies (HST) process for the evaluation of therapies for rare diseases. In this blog, we examine the key differences between the Single Technology Appraisal (STA) and the HST processes. There are numerous differences between the two processes; from timescale to individual requirements. Formal guidelines for the HST process are available here.

The NICE HST process (1/3) – origins and current state of affairs
Treatments for very rare conditions represent a unique challenge to payers. Extremely low patient numbers mean that often only Phase 1/2 trial data are available, and that natural history, quality of life and resource use data are limited. Combined with high unit costs, these evidence challenges result in estimates of cost-effectiveness that are subject to a greater degree of uncertainty.
The Health Technology Assessment (HTA) process is well-suited to the evaluation of therapies which are expected to benefit large numbers, but concerns exist as to their application to orphan therapies, and whether standard HTA processes accurately reflect societal preferences for treating rare diseases (1).

Is the NICE FTA process resulting in faster access to the most cost-effective therapies?
On the 1st April 2017, the National Institute for Health and Care Excellence (NICE) introduced a fast-track appraisal (FTA) process, with the aim of providing quicker access for patients to the most cost-effective new treatments. Two years on, has this objective been achieved? Since the introduction of the FTA process, final FTA guidance has been published for only four technologies (TA486, TA497, TA521 and TA572) [1]. All four therapies were considered based on a cost-comparison.

Will discount rates change for UK HTA
Written by David Trueman, Director
The rate at which future costs and outcomes are discounted has long stood at ...
No results found.